Public Market Listing
ACWASX
Live quotes, historical charts, and market capitalization for Actinogen Medical (ASX: ACW) are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Emestedastat(Xanamem) | Phase 2/3 | 11-beta-HSD1Small molecule | Alzheimer's DiseaseMajor Depressive Disorder |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (3)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-H1 | — | — | — | $4.3M | report ↗ |
View 2 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | — | $3.0M | $14M | $5.4M | report ↗ |
| 2024-H1 | — | — | — | $7.5M | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $4.0M | $9.5M | report ↗ |
Actinogen Medical (ASX: ACW) reported cash and equivalents of $4M and a quarterly net burn of $9.53M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | — | — | $6.2M | report ↗ |